Skip to main content
Clinical Trials/ACTRN12611000969965
ACTRN12611000969965
Terminated
Phase 2

A randomized controlled trial of intra-arterial reperfusion therapy after standard dose intravenous t-PA within 4.5 hours of ischemic stroke onset utilizing dual target vessel occlusion and penumbral mismatch imaging selection

Florey Institute of Neuroscience and Mental Health0 sites100 target enrollmentSeptember 9, 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Ischemic stroke
Sponsor
Florey Institute of Neuroscience and Mental Health
Enrollment
100
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Florey Institute of Neuroscience and Mental Health

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients presenting with anterior circulation acute ischaemic stroke eligible using standard criteria to receive IV tPA within 4\.5 hours of stroke onset
  • 2\. Patient, family member or legally responsible person depending on local ethics requirements has given informed consent
  • 3\. Patient's age is \>/\=18 years
  • 4\. Intra\-arterial clot retrieval treatment can commence (groin puncture) within 6 hours of stroke onset.
  • Imaging inclusion criteria
  • Dual target:
  • 5\. Arterial occlusion on CTA or MRA of the ICA, M1 or M2
  • 6\. Mismatch \- Using CT or MRI with a Tmax \>6 second delay perfusion volume and either CT\-rCBF or DWI infarct core volume.
  • a) Mismatch ratio of greater than 1\.2, and
  • b) Absolute mismatch volume of greater than 10 ml, and

Exclusion Criteria

  • 1\. Intracranial haemorrhage (ICH) identified by CT or MRI
  • 2\. Rapidly improving symptoms at the discretion of the investigator
  • 3\. Pre\-stroke mRS score of \>/\= 2 (indicating previous disability)
  • 4\. Inability to access the cerebral vasculature in the opinion of the neurointerventional team
  • 5\. Contra indication to imaging with MR with contrast agents
  • 6\. Participation in any investigational study in the previous 30 days
  • 7\. Any terminal illness such that patient would not be expected to survive more than 1 year
  • 8\. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
  • 9\. Pregnant women (clinically evident)
  • 10\. Previous stroke within last three months

Outcomes

Primary Outcomes

Not specified

Similar Trials